XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Stock-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2018 Incentive Plan activity and related information follows:

 

  

Shares

Available

for Grant

  

Number

of Options

Outstanding

  

Number

of RSUs

Outstanding

  

Weighted

Average

Exercise Price

 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   442    428    22   $59.23 
RSUs vested   -    -    (14)  $- 
RSUs granted   (9)   -    5   $- 
Options granted   (298)   298    -   $5.96 
Options forfeited/expired   235    (235)   -   $- 
RSUs forfeited/expired   2    -    (1)  $- 
Performance RSUs forfeited/expired   15    -    (7)  $- 
Balance at September 30, 2023   387    491    5   $27.31 
Options exercisable at September 30, 2023        140        $98.80 
Schedule of Assumptions Used to Calculate Fair Value of Stock Options

During the nine months ended September 30, 2023, the Company granted 178,000 employee and non-employee stock option awards. The assumptions used to calculate the Black-Scholes grant date fair value of such awards were as follows:

 

   Nine Months Ended 
   September 30, 
   2023   2022 
Expected life (in years)   6.25    5.98 
Risk-free interest rates   3.76%   2.29%
Volatility   105.99%   106.85%
Dividend yield   0%   0%
Summary of Stock-based Compensation Expense

Oncocyte recorded stock-based compensation expense in the following categories on the accompanying consolidated statements of operations:

 

   2023   2022   2023   2022 
   Three Months Ended   Nine Months Ended 
   September 30,   September 30, 
   2023   2022   2023   2022 
   (In thousands) 
Cost of revenues  $(2)  $94   $10   $239 
Research and development   294    521    931    1,416 
Sales and marketing   64    942    216    1,681 
General and administrative   252    1,624    1,119    4,087 
Total  $608   $3,181   $2,276   $7,423 
2010 Plan Activity [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Summary of Stock Option Activity

A summary of Oncocyte’s 2010 Plan activity and related information follows:

 

   Shares   Number   Weighted 
   Available   of Options   Average 
Options  for Grant   Outstanding   Exercise Price 
   (In thousands, except weighted average exercise price) 
Balance at December 31, 2022   -    30   $80.78 
Exercised   -    -   $- 
Cancelled   -    (20)  $- 
Balance at September 30, 2023   -    10   $73.22 
Exercisable at September 30, 2023        10   $73.22